Welcome to SaluTech

SaluTech is developing a safe Conductive Biomaterial (CBM) to treat Atrial Fibrillation by resynchronizing the electrical propagation in the heart. CBM is a non-toxic, long-lasting, and biocompatible nano-membrane that is able to mimic the conductive velocity of healthy heart tissue. The technology was originally developed within the University Health Network, and is patent protected. SaluTech is currently completing large animal studies, and looking to move forward to start clinical trials.

Ren-Ke Li, MD/PhD
Co-Founder, Chief Scientific Officer

Dr. Ren-Ke Li is a Professor of Medicine in the Department of Surgery, and a Senior Scientist at University Health Network. He has over 30 years of experience in the cardiovascular field.

Shuhe Li, JD/MBA
Co-Founder, Chief Executive Officer

Shuhe Li was previously an Investment Banking Associate at BMO Capital Markets in the North American Financial Institutions group.